Melphalanflufenamid (1) – Pepaxti®

Multiple myeloma (MM) after at least 3 previous therapies, combination with dexamethasone)

Characteristics

Start date 01.10.2022 – Marketing authorisation: 17.08.2022
Resolution 16.03.2023
INN Melphalanflufenamid
Brand name Pepaxti®
Pharm. company Oncopeptides AB
G-BA Procedure ID D-868
ATC code L01AA10 Nitrogen mustard analogues (L01AA)
ICD-10 codes (AIS) C90.00Multiple myeloma with failed remission, C90.01Multiple myeloma in remission
Alpha-ID codes (AIS) I21328Multiple myeloma, I31059Multiple myeloma in complete remission
Therapeutic area Oncological diseases Multiple myeloma (MM)
Reason for procedure Initial assessment
Specialty ACT change

Therapeutic indication of the resolution

Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapy, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one CD38 monoclonal antibody, and who have demonstrated disease progression during or after the last line of therapy. In patients with previous autologous stem cell transplantation, the time to progression after transplantation should be at least 3 years.

Subpopulation Indication Comparator
Adults with multiple myeloma who have received at least three prior lines of therapy, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38 monoclonal antibody, and who have demonstrated disease progression during or after the last therapy; time to progression at least three years for those with prior autologous stem cell transplantation Patient-individual therapy with selection of: - Bortezomib monotherapy - Bortezomib + pegylated liposomal doxorubicin - Bortezomib + dexamethasone - Carfilzomib + lenalidomide and dexamethasone - Carfilzomib + dexamethasone - Daratumumab + lenalidomide + dexamethasone - Daratumumab + bortezomib + dexamethasone - Daratumumab monotherapy (only for people with disease progression on last therapy) - Daratumumab + pomalidomide + dexamethasone - Elotuzumab + lenalidomide + dexamethasone - Elotuzumab + pomalidomide + dexamethasone (only for people with disease progression on last therapy) Isatuximab + pomalidomide + dexamethasone (only for people with disease progression on last therapy) - Ixazomib + lenalidomide + dexamethasone - Lenalidomide + dexamethasone - Panobinostat + bortezomib and dexamethasone - Pomalidomide + bortezomib and dexamethasone - Pomalidomide + dexamethasone (only for those with disease progression on last therapy) - Cyclophosphamide (in combination with other antineoplastic drugs) - Melphalan - Doxorubicin - Carmustine (in combination with other cytostatic drugs and an adrenocortical hormone, especially prednisone) - vincristine - Dexamethasone - Prednisolone - prednisone - Best Supportive Care taking into account previous therapies and the degree and duration of response.

Studies and Results

No. of studies
(best subpopulation)
1 (OCEAN) 0 (Data not accepted)
Study design
(best subpopulation)
Data not accepted (Dossier: H2H vs. ACT)
ACT change 27.09.2022 – Stellungnahme der Fachgesellschaften, Neue G-BA Beschlüsse

  • Clinical trials
    • In the randomised, open-label, controlled Phase III OCEAN trial, treatment with melphalan flufenamide in combination with dexamethasone was compared with the combination therapy of pomalidomide and dexamethasone (Pd).
    • The single-arm, open-label Phase II HORIZON trial, which investigated treatment with melphalan flufenamide in combination with dexamethasone, enrolled patients with relapsed, refractory multiple myeloma who had received at least two prior lines of treatment, including an immunomodulatory agent and a proteasome inhibitor.

Adults with multiple myeloma who have previously received at least three lines of treatment, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one monoclonal CD38 antibody, and who have shown disease progression during or after their most recent treatment; time to progression of at least three years in patients who have previously undergone an autologous stem cell transplant

  • An additional benefit is not proven.
  • There are therefore no suitable data available to demonstrate any additional benefit of melphalan flufenamide in combination with dexamethasone compared with the appropriate comparator therapy.
  • Overall assessment
    • As there are therefore no suitable data to provide proof of an additional benefit of melphalan flufenamide in combination with dexamethasone compared with the appropriate comparator therapy, an additional benefit of melphalan flufenamide in combination with dexamethasone is not proven.

Courtesy translation only, please refer to the German original.

Associated procedures

Melphalanflufenamid (2) Pepaxti® Oncopeptides AB Oncological diseases Multiple myeloma, refractory, after 2 prior therapies, combination with dexamethasone n.d. discontinued
Melphalanflufenamid (1) Pepaxti® Oncopeptides AB Oncological diseases Multiple myeloma (MM) after at least 3 previous therapies, combination with dexamethasone) 1,200–1,300 100% additional benefit not proven


<< List of all resolutions